Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 167,852	$ 144,761
Accounts receivable, net	140,190	80,142
Inventories, net	105,124	94,491
Prepaid clinical development costs	4,044	586
Prepaid inventory costs	40,864	13,863
Other prepaid and current assets	4,496	4,155
Total current assets	462,570	337,998
Property and equipment, net	338	254
Right of use operating lease assets	2,922	5,513
Intangible assets	56	56
Total assets	465,886	343,821
Current liabilities:
Accounts payable	65,068	51,650
Convertible notes, net of issuance costs	0	54,575
Accrued clinical development costs	4,115	5,035
Accrued variable consideration	88,203	56,535
Other accrued liabilities	19,249	19,593
Royalty sale liability	87,596	47,586
Deferred revenue from collaborations	34,477	8,518
Operating lease liabilities	2,102	2,741
Total current liabilities	300,810	246,233
Convertible notes, net of issuance costs	97,260	96,745
Royalty sale liability	208,170	246,024
Long-term debt	152,219	140,971
Operating lease liabilities	653	2,570
Other long-term liabilities	8,739	0
Total liabilities	767,851	732,543
Commitments and contingencies (Note 5)
Stockholders’ deficit:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and December 31, 2024	0	0
Common stock, $0.001 par value; 480,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 247,210,341 shares issued at December 31, 2025 and 197,846,661 shares issued at December 31, 2024	245	196
Additional paid-in capital	1,376,499	1,267,109
Treasury stock, at cost; 1,994,198 shares at December 31, 2025 and December 31, 2024	(54,998)	(54,998)
Accumulated other comprehensive loss	0	0
Accumulated deficit	(1,623,711)	(1,601,029)
Total stockholders' deficit	(301,965)	(388,722)
Total liabilities and stockholders' deficit	$ 465,886	$ 343,821